High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Issue 8 (August 2013)

• Record Type: Journal Article
• Authors: Herold, Tobias; Mulaw, Medhanie A.; Jurinovic, Vindi; Seiler, Till; Metzeler, Klaus H.; Dufour, Annika; Schneider, Stephanie; Kakadia, Purvi M.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, Christian; Dreyling, Martin; Bohlander, Stefan K.
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 8(2013:Aug.)
• Page Start: 1652
• Page End: 1657
• Publication Date: 2013-08
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2012.753445
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We recently identified the marginal zone B and B1 cell-specific protein (<italic>MZB1</italic>) as part of a gene expression signature associated with outcomes in chronic lymphocytic leukemia (CLL). <italic>MZB1</italic> is important for B cell function as a key regulator of antibody secretion, calcium homeostasis and adhesion. Therefore, we analyzed the role of <italic>MZB1</italic> expression levels in 139 patients with CLL using quantitative real-time polymerase chain reaction (qRT-PCR) and microarray data sets in CLL, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and acute myeloid leukemia (AML). High <italic>MZB1</italic> expression was associated with inferior survival in CLL (hazard ratio [HR]: 1.63 [confidence interval (CI): 1.14–2.33], <italic>p</italic> = 0.007), FL (221286_s_at HR: 1.16 [CI: 0.98–1.37], <italic>p</italic> = 0.086; 223565_at: HR: 1.3 [CI: 1.1–1.61], <italic>p</italic> = 0.015) and DLBCL (221286_s_at: HR: 1.17 [CI: 1.06–1.3], <italic>p</italic> = 0.003; 223565_at: HR: 1.21 [CI: 1.08–1.35], <italic>p</italic> = 0.001). In DLBCL <italic>MZB1</italic> expression was an additive prognostic marker in a multivariate model including activated B-cell like (ABC) versus germinal center (GCB) subtype. Additionally, <italic>MZB1</italic> expression correlated with a unique gene expression pattern. This study is the first to show that the expression level of a single gene has prognostic significance in different lymphoma subtypes. Due to its biological function, <italic>MZB1</italic> may play a central role in B cell neoplasms and is a potential target for future therapeutic interventions.</p> </abstract>